Alpha-Lipoic Acid: R-ALA vs S-ALA and Why a Racemic Bottle Wastes Half the Dose

Walk any supplement aisle and pick up a bottle of alpha-lipoic acid. The number on the front is almost always 300 mg, 600 mg, or 1,200 mg. The supplement-facts panel lists "alpha-lipoic acid" as a single ingredient and moves on. Nothing on the label tells you what shape the molecule is in.

ALA is a chiral molecule. It exists as two mirror-image isomers: R-ALA and S-ALA. R-ALA is the naturally occurring, biologically active form — the one your mitochondria synthesize in small amounts as a cofactor for pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase, the two enzyme complexes at the entry and midpoint of the citric acid cycle. S-ALA does not occur in nature. It is the synthetic byproduct produced in a roughly 50/50 mix whenever ALA is manufactured through the standard chemical route.

A "racemic" ALA bottle is that 50/50 mix. A 600 mg racemic capsule is functionally a 300 mg R-ALA dose paired with 300 mg of a mirror-image molecule that does not participate in the mitochondrial reactions the R form drives. If S-ALA were inert, this would be a straightforward "you paid twice for half a dose" problem. If S-ALA is antagonistic — some in vitro work suggests it competes with R-ALA for uptake and some downstream reactions — then a racemic bottle is worse than paying twice for half a dose; it is paying twice for a diluted-and-blunted dose.

This is the same isomer-blindness pattern that runs through the inositol myo-vs-D-chiro 40:1 ratio problem, the vitamin K2 MK-4 vs MK-7 form question, and the choline alpha-GPC vs bitartrate yield gap. The number on the front of the bottle is doing work the correct isomer or form should be doing.

What Alpha-Lipoic Acid Actually Does

ALA is a sulfur-containing cofactor covalently attached to lysine residues in three mitochondrial enzyme complexes: pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, and the branched-chain alpha-ketoacid dehydrogenase. In this endogenous role, it participates in substrate-oxidation reactions as the enzyme complexes convert pyruvate to acetyl-CoA, alpha-ketoglutarate to succinyl-CoA, and branched-chain amino acids into their downstream metabolites. Total endogenous ALA is measured in micrograms and is protein-bound; free ALA in circulation is essentially absent under normal conditions.

Supplemental ALA is a very different molecule from the perspective of biology. Oral doses of hundreds of milligrams to a couple of grams produce short-lived plasma peaks of free ALA — not the protein-bound cofactor form — that transiently reach concentrations three to four orders of magnitude above physiologic. In this free, unbound, supra-physiologic form, ALA is functioning as a small-molecule antioxidant and metal chelator with a set of properties that do not fully overlap with the mitochondrial-cofactor role.

Three broad functional groups matter for supplementation.

Recycling of other antioxidants. Reduced ALA (dihydrolipoic acid, DHLA) regenerates oxidized vitamin C, vitamin E, and glutathione. This is one of the properties often cited when ALA is called a "universal antioxidant" — it operates in both aqueous and lipid phases and recycles the vitamin-C and vitamin-E pools that would otherwise stay oxidized.

Metal chelation. ALA and DHLA bind iron, copper, mercury, cadmium, and lead. This is a genuine pharmacologic property and has been explored in heavy-metal exposure protocols.

Insulin-signaling and glucose-uptake modulation. Supra-physiologic ALA activates AMP-kinase and modulates insulin-receptor signaling in a manner that improves glucose uptake in insulin-resistant tissues at the trial doses that have shown a signal in diabetic-neuropathy and metabolic-syndrome studies.

The trial evidence lives almost entirely in R-ALA territory. The intravenous protocols that produced the initial diabetic-neuropathy signal in the German and Eastern European literature used pure or R-enriched formulations. The oral trials that have followed have used racemic ALA at doses high enough that the R content clears the effective threshold even when it is only half the label number — but this is a workaround, not a design. Where R-only oral formulations have been trialed head-to-head against racemic at matched R content, the R-only formulations produce higher and more consistent plasma peaks.

What the Isomers Actually Are

Chirality is the property of a molecule that has a mirror-image partner that cannot be superimposed on it — the same way a left and right hand share every dimension but cannot be laid on top of one another. R and S are the naming convention for which mirror-image version you have.

ALA has a single chiral center at the carbon bearing the third sulfur of its five-carbon backbone. The R configuration is the one enzymes evolved to recognize; the enzyme active sites are shaped for R-ALA and do not accept S-ALA as a substrate for the mitochondrial reactions.

Synthetic ALA is manufactured through a route that produces R and S in a 50/50 mixture — a racemate — because the chemistry does not distinguish between the two configurations at the reaction step that sets the chiral center. Separating the R from the S is possible (chiral chromatography, enzymatic resolution) but adds significant cost, which is why the standard commercial product is the racemate and R-only bottles command a premium.

The important consequence: R-ALA is what the enzymes and receptors accept. S-ALA is a mirror-image passenger that does not participate in the mitochondrial-cofactor role. The in vitro work on S-ALA is not fully settled, but the general picture is that S-ALA is far less active as an antioxidant, does not participate in the insulin-signaling pathway at the same potency, and in some experimental setups appears to interfere with the R form's activity.

A 600 mg racemic capsule delivers 300 mg of R-ALA — the biologically active dose — plus 300 mg of S-ALA that at best does nothing useful and at worst runs interference on the reactions you are dosing for.

What the Research Actually Doses

The controlled-trial literature on ALA spans a handful of use cases. In every one, the effective dose starts around 300 to 600 mg of R-ALA equivalent per day. Below that, the signal is weak.

• Diabetic peripheral neuropathy: 600 mg/day for 5 weeks (oral). The ALADIN, SYDNEY, and NATHAN trial series established the 600 mg oral dose as the standard therapeutic entry point. These trials used racemic ALA, meaning the effective R content was ~300 mg — enough to clear the threshold, but leaving performance on the table relative to what an R-only 600 mg dose would deliver.
• Diabetic neuropathy, higher-severity or intravenous protocols: 600 to 1,200 mg/day. Intravenous trials have used doses in this range with more pronounced short-term symptom reduction.
• Insulin sensitivity in type 2 diabetes / metabolic syndrome: 600 to 1,800 mg/day, split-dose. The oral protocols that have shown insulin-sensitivity signal typically run at the higher end, 900 to 1,800 mg/day of racemic (450 to 900 mg R-ALA).
• Weight-management adjunct: 1,200 to 1,800 mg/day. A meta-analysis pooled the modest weight-loss signal from these doses; the effect size is small and the clinical relevance is debatable, but the trial dose is well above single-capsule-of-300-mg territory.
• Non-alcoholic fatty liver disease / hepatic-injury adjunct: 600 to 1,200 mg/day. Small trials at these doses have shown modest improvement in transaminases.

The convergence point across the modern indications is 300 mg of R-ALA as the effective floor and 900 mg of R-ALA as the upper end for most oral indications. A single 300 mg racemic capsule daily — the most common consumer purchase — delivers ~150 mg of R-ALA, which is below the trial floor for every indication ALA is used for. It is a marketing shape that costs the consumer real money and delivers a plasma peak that will not measure on any endpoint the trial literature has documented.

The Stability Problem and Why Sodium R-Lipoate Exists

Pure R-ALA has a problem: it is unstable. R-ALA is a solid at room temperature only because its molecules polymerize into a rubbery, insoluble mass at temperatures above about 45 °C — a temperature it can hit inside a shipping container in summer or on a warehouse shelf. Once polymerized, R-ALA is neither dissolvable nor bioavailable. Early R-only bottles that shipped as free R-ALA acid arrived on customer shelves partly polymerized and dosed inconsistently, and the industry retreated to racemic — which is more stable because the S isomer packs the crystal lattice differently and resists polymerization.

Sodium R-lipoate (Na-R-ALA) solves this. The sodium salt of R-ALA does not polymerize at room temperature, is stable to shipping and shelf-life, and dissolves cleanly in the stomach. The trade-off is a slightly higher cost per gram of R-ALA delivered — the sodium contributes to the total mass, so a 300 mg sodium R-lipoate capsule delivers ~272 mg of R-ALA free acid equivalent (roughly 90% of the label number, because the sodium counts toward the mass). Modern R-only formulations that are worth buying use sodium R-lipoate rather than free R-ALA acid.

Practical label-read: a bottle listing "R-alpha-lipoic acid" without further qualification may be free R-ALA acid, which has the stability problem. A bottle listing "sodium R-lipoate" or "Na-R-ALA" or "K-R-ALA" (potassium R-lipoate) has solved the stability problem. A bottle listing just "alpha-lipoic acid" is racemic, and half the label number is doing nothing useful.

Timing and Split-Dose

Oral ALA has a very short plasma half-life — roughly 30 minutes. A single 600 mg oral dose peaks in plasma within 30-60 minutes and returns to near-baseline within 3-4 hours. Steady-state tissue effects have not been fully mapped for the antioxidant and insulin-signaling roles, but the acute peak is what most trials have used as the pharmacologic driver.

The practical protocol most trials use:

• Single 300-600 mg dose taken 30 minutes before a meal. Food substantially reduces the plasma peak, so most trials time the dose empty-stomach. For diabetic neuropathy the 600 mg once-daily protocol is the standard.
• Split-dose 300 mg twice daily for the higher-dose insulin-sensitivity indications where 900-1,800 mg/day totals are used. Two split doses maintain plasma exposure across more of the day.
• Not with a meal that contains meaningful iron or copper. ALA chelates both. The chelation is short-lived given the plasma half-life, but the recommendation is to space the ALA dose from a multivitamin with mineral content or an iron supplement.

Chronic loading beyond a few weeks does not appear to build a reservoir the way creatine or beta-alanine do. ALA is used in an acute-plasma-peak model, not a chronic-loading model.

Why the 300 mg Once-Daily Racemic Capsule Is the Worst Shape

The most common consumer purchase pattern for ALA is a 300 mg racemic capsule taken once daily with breakfast. This shape fails on three levers simultaneously.

Isomer content. Half the 300 mg is S-ALA. Effective R dose: ~150 mg. Below trial floor.

Taken with food. Food reduces plasma peak substantially. The AUC drops meaningfully compared with an empty-stomach dose.

Once daily against a 30-minute half-life. Whatever plasma peak the dose produces is gone within 4 hours. The 20 remaining hours of the day are functionally unmedicated.

The consumer takes the capsule for 90 days, sees nothing, and either quits the category or doubles down and buys a larger racemic bottle — usually 600 mg once daily with food — that still fails on two of the three levers.

The upgraded shape is: 600 mg sodium R-lipoate taken 30 minutes before breakfast, or 300 mg sodium R-lipoate taken twice daily 30 minutes before two meals. This delivers roughly 540-540 mg of R-ALA equivalent across the day at empty-stomach peaks, which is in the range every trial signal has come out of.

What to Look For on the Label

Six checks that separate a real ALA product from a marketing shape.

1. Isomer specification. Look for "R-alpha-lipoic acid" or "sodium R-lipoate" or "Na-R-ALA" explicitly. A bottle that says only "alpha-lipoic acid" is racemic; half of what you are paying for is S-ALA.

2. Stability form. For R-only bottles, prefer sodium R-lipoate (or potassium R-lipoate) over free R-ALA acid. The sodium salt does not polymerize; the free acid can.

3. Dose per serving in R-ALA equivalent terms. A 600 mg racemic bottle delivers 300 mg R-ALA. A 300 mg sodium R-lipoate bottle delivers ~272 mg R-ALA free-acid equivalent. Compare apples-to-apples in R content, not label number.

4. No proprietary blend hiding the isomer. ALA in a "metabolic support" or "insulin support" proprietary blend is almost always racemic and almost always at a sub-trial dose. See the proprietary-blends underdosing pattern. If the blend does not disclose the ALA content and isomer separately, treat it as absent.

5. Empty-stomach dosing direction. A bottle that instructs "take with food" is either uninformed or trying to protect a subset of users from mild GI discomfort — either way, the plasma peak drops with food. Empty-stomach dosing is the trial-consistent instruction.

6. Not paired with iron in a single formula. ALA chelates iron. A one-a-day multi that combines ALA with 18 mg of iron is a formulation error — either the iron is not absorbed or the ALA is not absorbed, depending on gastric transit timing.

What ALA Is Not

Three claims worth pushing back on.

"Miracle antioxidant / universal antioxidant." ALA is a real antioxidant with a real ability to recycle other antioxidants. It is not a special substance that transcends the class. The plasma peak is short-lived and the endogenous glutathione, vitamin C, and vitamin E systems are the ones doing most of the antioxidant work over a 24-hour day. ALA is a useful adjunct in the indications with trial evidence, not a foundational daily supplement for everyone.

"Fat burner." The weight-loss meta-analytic effect at 1,200-1,800 mg/day is roughly 1-2 kg over 8-16 weeks — modest, clinically borderline, and not a category-defining fat-loss intervention. Marketing that positions ALA as a fat burner is overselling a small signal.

"Detox." The metal-chelation property is real for heavy metals, but the "detox" framing generally implies clearance of a poorly-defined burden that has never been quantified. In documented heavy-metal exposure, ALA is one of several chelation options and is used under clinical supervision. In the absence of documented exposure, the "detox" framing is a marketing overlay on a molecule that does not need one.

The Bottom Line

Alpha-lipoic acid exists as R-ALA (biologically active, occurs naturally in mitochondria) and S-ALA (synthetic byproduct of chemical manufacture, inactive or possibly antagonistic). A standard "ALA" bottle is a 50/50 racemic mix, meaning half the label number is doing no useful work and possibly running interference on the half that is. The trial evidence for diabetic neuropathy, insulin sensitivity, and NAFLD adjunct uses 300-900 mg of R-ALA equivalent per day, empty-stomach, ideally split-dosed. The most common consumer purchase — 300 mg racemic once daily with breakfast — delivers ~150 mg of R-ALA, taken at a reduced plasma peak, once against a 30-minute half-life. It fails on isomer content, food interaction, and dose frequency in one shape.

The upgrade is sodium R-lipoate (or potassium R-lipoate) at 300 mg twice daily or 600 mg once daily, 30 minutes before a meal, spaced from iron-containing multis. That protocol matches what the trial literature has actually used to produce signal on the endpoints ALA is used for.

The label read is short: if it does not say R-lipoate somewhere on the front or the supplement-facts panel, it is racemic. If it lists sodium R-lipoate, the stability problem is solved. If it lists free R-ALA acid, keep it out of the heat. And if a 30-count bottle of 300 mg racemic ALA is being sold as a metabolic-support once-a-day capsule to be taken with breakfast, the shape is wrong on three levers before the molecule ever reaches your bloodstream.

The transparency thread on this site — the how to read a supplement label in 60 seconds, the inositol form question, the choline yield gap, the magnesium form matrix — is the same pattern with different molecules. The shape of the label is not the shape of the dose. R-ALA versus racemic ALA is the version of that pattern that costs the neuropathy patient half his effective dose without ever showing up on the front of the bottle.